Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became apparent that the efficacy of adalimumab in daily practice was highly variable. In our review, we highlighted the current evidence from literature on the use of biologics in HS in a real-life setting, particularly adalimumab, secukinumab and ustekinumab. Data on the effectiveness and safety of biologic drugs in HS management have been analyzed. Even if the results are promising, more studies are needed. In our opinion, the armamentarium of drugs for HS management is increasing, and treatment will be based on a tailored-tail approach, minimizing the risk of adverse events. In this context, we want to point out the reported effectiveness and safety data concerning adalimumab, ustekinumab and secukinumab as well as ixekizumab.

Automated summary

To date, adalimumab is the only approved biotechnology drug for managing hidradenitis suppurativa (HS), but its efficacy in real-life practice varies. This review analyzes the current evidence on the use of biologics in HS, particularly adalimumab, secukinumab, ustekinumab, and ixekizumab. While the results are promising, more studies are needed. The armamentarium of drugs for HS management is expanding, allowing for personalized treatment approaches to minimize adverse events.